This competitive grant program seeks to support research conducted by Junior Investigators that advances medical knowledge in the understanding, diagnosis and treatment of ATTR Amyloidosis.
Pfizer is interested in supporting research proposals that advance our understanding of the epidemiology, basic science and early diagnosis and treatment of ATTR amyloidosis through research focused in the following areas:
Epidemiologic evaluations for ATTR amyloidosis
Approaches for the early identification and follow up of ATTR amyloidosis patients
RW efficacy and safety of tafamidis in the clinical setting for the management of ATTR amyloidosis
Evaluation of patients with ATTR-CM presenting with a mixed phenotype (e.g. cardiomyopathy and polyneuropathy)